Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 4/20 | 0.31 |
| ▸ | CES1 | P23141 | 4/20 | 0.31 |
| ▸ | CES2 | O00748 | 3/20 | 0.31 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134758 | 0.99 | EPHX1 (0.37) | CA1CA2EPHX1LMNACTSK | |
| SCHEMBL2136273 | 0.96 | EPHX1 (0.37) | CA1CA2EPHX1LMNAFAAH | |
| SCHEMBL2139744 | 0.96 | CA2 (0.37) | CA1CA2EPHX1LMNACTSK | |
| SCHEMBL2135586 | 0.95 | EPHX1 (0.39) | EPHX1LMNAFAAHCES1CES2 | |
| SCHEMBL2134711 | 0.93 | EPHX1 (0.33) | CA1CA2EPHX1LMNA | |
| SCHEMBL2135940 | 0.92 | LMNA (0.36) | CA1CA2EPHX1LMNAFAAH | |
| SCHEMBL2135667 | 0.92 | EPHX1 (0.35) | CA1CA2EPHX1LMNAFAAH | |
| SCHEMBL2139757 | 0.90 | EPHX1 (0.36) | CA1CA2EPHX1LMNACTSK | |
| SCHEMBL2133798 | 0.89 | CA1 (0.36) | CA1CA2EPHX1CTSKFAAH | |
| SCHEMBL2136012 | 0.89 | EPHX1 (0.38) | CA1CA2EPHX1LMNACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664613-A1 | Process for producing amide compounds | Sumitomo Chemical Company, Limited (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-2662355-A1 | Process for producing a (fluoroalkylthio) acetonitrile | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2465846-A1 | PROCESS FOR PREPARATION OF (FLUOROALKYLTHIO)ACETIC ACID ESTERS | Sumitomo Chemical Company, Limited (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | GRHPR, AKR7A2, FAR1 | CA1 617/4885CA2 737/4885EPHX1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.